TBK1 and myelofibrosis: CYT387, a drug for the treatment of myelofibrosis, can inhibit interferon and interferon-stimulated gene expression through JAK1/JAK2 (kinases mediating IFN signaling) and TBK1/IKKε (kinases mediating RLR and TLR signaling) pathways27.